Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Episode 26 December 07, 2022 00:39:02
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.
Few & Far Between: Conversations from the Front Lines of Drug Development
Episode 26: Chris Min, CMO and Interim CEO at Longeveron, Inc.

Dec 07 2022 | 00:39:02

/

Show Notes

"Try to find the people who have a really strong background in regulatory science, who really understand the fundamentals, and who you believe can think creatively about the challenges of the cell therapy space." - Chris Min, Longeveron

Biorasi welcomes Chris Min to the Few & Far Between podcast for an inside look at the cell therapy industry and the importance of finding the right team to support your clinical trials. 

Other Episodes

Episode 37

January 24, 2024 00:41:31
Episode Cover

Episode 37: Will Greene, Prader-Willi Syndrome patient advocate, Healthcare Engagement Lead at Roche

"The history of rare disease drug development indicates that once you start looking harder for cases, you often tend to find them." - Will...

Listen

Episode 10

September 15, 2021 00:44:02
Episode Cover

Episode 10: Sharon Terry, CEO Genetic Alliance

Why is the sharing of data so crucial to #raredisease research? Tune in for today's full episode of Few & Far Between. Episode 10...

Listen

Episode 21

June 23, 2022 00:36:29
Episode Cover

Episode 21: Jill Hawkins, Founder and President of the FAM177A1 Research Fund

How do you start in building a rare disease foundation? Biorasi's Few & Far Between Podcast Welcomes Jill Hawkins, Founder and President of the...

Listen